Solvent: A Framework for Protein Folding

Consistency and reliability are crucial for conducting AI research. Many famous research fields, such as object detection, have been compared and validated with solid benchmark frameworks. After AlphaFold2, the protein folding task has entered a new phase, and many methods are proposed based on the component of AlphaFold2. The importance of a unified research framework in protein folding contains implementations and benchmarks to consistently and fairly compare various approaches. To achieve this, we present Solvent, an protein folding framework that supports significant components of state-of-the-art models in the manner of off-the-shelf interface Solvent contains different models implemented in a unified codebase and supports training and evaluation for defined models on the same dataset. We benchmark well-known algorithms and their components and provide experiments that give helpful insights into the protein structure modeling field. We hope that Solvent will increase the reliability and consistency of proposed models and gives efficiency in both speed and costs, resulting in acceleration on protein folding modeling research. The code is available at https://github.com/kakaobrain/solvent, and the project will continue to be developed.Comment: preprint, 8page

Eco-friendly Technologies for Physical and Chemical Recycling of PVC-Related Wasteful Resources

The aim of this study is to enhance the recycled PVC related material property by formulation technology and develop the recycling product processing technology furthermore develop the chemical recycling technology for last stage of PVC wastes. The formulation technology is composed of pre-treatment (crushing, separation etc.) and post-treatment (material ratio, additives, stabilizer etc.) to enhance the recyclate property. The formulation for recycled PVC by application basis and processing technology is applied to produce the structural product for civil and construction application such as pipe fittings and water drainage cap for environmental waterway. Also chemical recycling technology for end life PVC scrap which causes environmental pollution by incineration or landfill is studied for producing hydrocarbon and hydrogen chloride for VCM

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

The Optimal Cost Estimating for Improvement of Product Design

While the concepts of design for manufacturability and concurrent engineering have made significant advances in integrating the design function with other areas in companies, major gaps remain in the timely and accurate provision of costing information to designers. Inappropriate design could increase the redesign cost and delay the product realization. This present 3-step research aims to reduce the design cost of the product. The first step sets up the optimal cost, which is the engineering target based on the function. The second step estimates the current function cost according to the unit through the function and quantitative analysis for the basic model. In the third step, the design of a unit is reviewed according to the priority of the difference between the optimal cost and the function cost. Arranging the unit design parameters, the best design option is set up according to the level

Carrier Harmonic Modulation for Simultaneous Wireless Information and Power Transfer

This paper presents the carrier harmonic modulation (CHM) for near-field data communication during wireless power transmission. The proposed CHM does not increase the coil dimension, and an additional data driver is not required. Compare to conventional modulation techniques such as frequency-shift keying (FSK) and amplitude-shift keying (ASK), the power delivered to the load (PDL) of CHM is independent of the data transmission. The prototype CHM provides a data rate of 1.1 Mbps while the power carrier frequency is also 1.1 MHz. It achieved a maximum PDL of 641 mW and the system efficiency of 17% with a 30 mm TX/RX coil diameter

Vehicle routing problem with vector profits with max-min criterion

<p>This article introduces a new routing problem referred to as the vehicle routing problem with vector profits. Given a network composed of nodes (depot/sites) and arcs connecting the nodes, the problem determines routes that depart from the depot, visit sites to collect profits, and return to the depot. There are multiple stakeholders interested in the mission and each site is associated with a vector whose <i>k</i>th element represents the profit value for the <i>k</i>th stakeholder. The objective of the problem is to maximize the profit sum for the least satisfied stakeholder, <i>i.e.</i> the stakeholder with the smallest total profit value. An approach based on linear programming relaxation and column-generation to solve this max–min type routing problem was developed. Two case studies—the planetary surface exploration and the Rome tour cases—were presented to demonstrate the effectiveness of the proposed problem formulation and solution methodology.</p